newsfilter
← Earnings
Earnings Releases·

BridgeBio — Third Quarter 2026 Earnings Summary

BridgeBio Pharma reported third-quarter 2026 total revenues of $353.2 million, driven primarily by $253.2 million in U.S. Attruby net product sales and a $75.0 million sales milestone from Bayer. The company recorded a loss from operations of $11.6 million and held $1.5 billion in cash, cash equivalents, and marketable securities as of September 30, 2026. Commercial progress for Attruby continues with real-world evidence demonstrating superior outcomes compared to tafamidis, while the company prepares for upcoming regulatory decisions on BBP-418, oral infigratinib, and encaleret.

Company
BRIDGEBIO PHARMA INC
Sector
Healthcare
Industry
Biotechnology